Navigation Links
Avalon Pharmaceuticals to Present at the American Association for,Cancer Research 2007 Annual Meeting

ancer targets. The company has value generating partnerships with Merck, MedImmune, Medarex, and Novartis. Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Md.

This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to progress in our drug discovery programs and our collaborations, and clinical progress in the development of AVN944. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties including the risk that the discovery programs and collaborations may not be successful and that AVN944 will not progress successfully in its clinical trials, and other risks described in our SEC filings. There can be no assurance that our development efforts will succeed, that AVN944 will receive required regulatory clearance or, even if such regulatory clearance is received, that any subsequent products will ultimately achieve commercial success. The information in this Release should be read in conjunction with the Risk Factors set forth in our 2005 Annual Report on Form 10-K and updates contained in subsequent filings we make with the SEC.

    Contacts:

    Avalon Pharmaceuticals, Inc.              Noonan Russo

    Gary Lessing                              Greg Geissman (Media)

    Executive Vice President & CFO            Tel: (619) 814-3510

    Tel: (301) 556-9900

    Fax: (301) 556-9910                       The Trout Group LLC

    Email:                   Chad Rubin (Investors)

                                              Tel: (646) 378-2947

info@avalonrx.com

CONTACT: Gary Lessing, Executive Vice President & CFO of AvalonPharmaceuticals, Inc., +1-301-556-9900, ; or
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:6/29/2015)... 29, 2015 The Parenteral Drug Association is ... Board of Professional Engineers and Land Surveyors ... to professional engineers for continuing professional competency (CPC) credits. ... value and quality of PDA,s professional education offerings," said ... and hands-on professional training at the Training and Research ...
(Date:6/29/2015)... , June 29, 2015  VisionCare Ophthalmic ... visual prosthetic devices for the treatment of ... publication of "Long-Term (60-month) Results for the ... Stratified by Age in Patients with End-Stage ... . The 5-year data show substantial retention ...
(Date:6/29/2015)... June 29, 2015 Dermatological drugs ... revenues ,Where is the market for dermatological drugs heading? ... Visiongain ,s new report shows you potential revenues and ... Our 310 page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 2Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 3Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 4Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8
... at the 2011 Pharmaceutical Care Management Association (PCMA),s ... President and CEO Eric Elliott speak about the ... managers as health care reform is implemented, industry ... the market and the pipeline of new treatments ...
... DALLAS, Feb. 8, 2011 ... known for its expertise in understanding consumer data, translating ... effective creative with measurable results, today announced that Peter ... Strategy - Healthcare.  Dannenfelser, a pharmaceutical marketing executive with ...
Cached Medicine Technology:Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 3
(Date:6/30/2015)... ... June 30, 2015 , ... This Fourth of July, Peacock ... Alley story including hard work, tenacity, perseverance, commitment to quality, honesty and love of ... Born of Mary Ella Gabler's simple love of quilts, Peacock Alley was fully realized ...
(Date:6/29/2015)... ... 2015 , ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame ... natural skincare and even culinary uses, was especially designed for Oil Pulling. , ... Oil Pulling can accomplish this. Oil Pulling is an Ayurvedic practice that is easy ...
(Date:6/29/2015)... ... June 30, 2015 , ... With thousands of children in ... in a much-needed autism support center, planned at Utah Valley University, in Orem, Utah. ... for the center and the building in which it will be housed. , Utah ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one ... Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons ...
(Date:6/29/2015)... ... 29, 2015 , ... The Society for Immunotherapy of Cancer ... granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of metastatic ... of nivolumab for patients with metastatic melanoma in Europe represents a major advance ...
Breaking Medicine News(10 mins):Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), announced ... (NDA) to the U.S. Food and Drug Administration ... approval for Xibrom QD,as a treatment for inflammation, ... ophthalmic solution), Xibrom is a topical non-steroidal ...
... Will Fund 20 Percent of Cost for New Hospital, ... that it has reached its $50 million Capital Campaign,goal, ... ever,undertaken. A recent gift of $500,000 from the Stephen ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071220/DC10448 ), "It,s only ...
... 20 Today URAC called for,comments on ... Health Web,Site, HIPAA Privacy (Business Associate and ... Covered Entity) accreditation programs.,URAC is seeking input ... care management organizations and health plans. The,deadline ...
... MCG Capital,Corporation (Nasdaq: MCGC ) today announced ... the acquisition of Gould & Lamb, LLC by ABRY,Partners ... company that is unique to,the workers, compensation industry. The ... workers, compensation industry,since 2001. Having completed in excess of ...
... ... Nataline Sarkisyan ... GLENDALE, Calif., Dec. 20 In a stunning turn around,insurance ... California Nurses Association/National Nurses Organizing Committee,helped to generate, and agreed ...
... of Howard G. Smith,announces a September 4, 2007, ... in,the securities class action lawsuit filed on behalf ... Pharmaceuticals, Inc. ("Threshold,Pharmaceuticals" or the "Company")(Nasdaq: THLD ... (the "Class Period"), including purchasers in Threshold,s,February 4, ...
Cached Medicine News:Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:MCG Capital Invests in Gould & Lamb 2Health News:CIGNA Capitulates to Patient Revolt 2Health News:CIGNA Capitulates to Patient Revolt 3Health News:Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc. 2
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: